New study: COVID-19 may cause or accelerate neurological diseases
Danish researchers published a study suggesting that COVID-19 increases the risk of neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease.
New Search
If you are not happy with the results below please do another search
Search
50 search results for:
Astellas and Sutro unite to overcome checkpoint inhibitor limitations with iADCs
/in Business, R&DTokyo-based Astellas Pharma and South San Francisco-based Sutro Biopharma have inked a global collaboration and licensing deal aimed at the discovery and development of novel immunostimulatory antibody-drug conjugates (iADCs).
Omicron sub-variants BA.4, BA.5 make up more than 50% of U.S. COVID cases – CDC
/in R&D, TherapeuticsThe fast-spreading BA.4 and BA.5 sub-variants of Omicron are estimated to make up a combined 52% of the coronavirus cases in the United States as of June 25, the U.S. Centers for Disease Control and Prevention (CDC) said on Tuesday.
U.S. FDA will decide on redesigned COVID vaccines by early July
/in R&D, TherapeuticsU.S. regulators plan to decide by early July on whether to change the design of COVID-19 vaccines this fall in order to combat more recent variants of the coronavirus, with hopes of launching a booster campaign by October, a top Food and Drug Administration official said on Tuesday.
Health at home on the main stage
/in Marketing & AdvertisingAward-winning creative Natxo Diaz reviews health’s debut performance on the main stage at Cannes – and sees a sector oozing confidence.
EU begins review of Bavarian Nordic’s vaccine for monkeypox
/in R&D, TherapeuticsThe European Union’s drug regulator said on Tuesday it has started a review to extend the use of Bavarian Nordic’s (BAVA.CO) smallpox vaccine to prevent monkeypox disease as well.
Oklahoma reaches $250M opioid settlement with drug distributors
/in TherapeuticsOklahoma has reached a $250 million settlement with AmerisourceBergen Corp., Cardinal Health Inc., and McKesson Corp. to resolve allegations the drug distributors contributed to the opioid epidemic in the state, Oklahoma Attorney General John O’Connor said on Monday.
U.S. appeals court vacates federal vaccine mandate pending additional hearing
/in TherapeuticsA U.S. appeals court panel said on Monday it would convene a full panel to reconsider President Joe Biden’s executive order requiring civilian federal employees to be vaccinated against COVID-19, and set aside the order pending that hearing.
Revolutionizing the Clinical Research Ecosystem with AI & ML
/in R&DAdopting digital transformation is now an industry standard for success – but what precisely does that mean for the clinical development landscape? Gary Shorter, Head of Artificial Intelligence at IQVIA, explores the answers.
GUIDEMARK HEALTH AND CYAN HEALTH ARE NOW LUMANITY
/in Marketing & AdvertisingGuidemark Health and Cyan Health have today rebranded, changing their names to Lumanity. The two agencies were acquired by Lumanity in 2021.
